Literature DB >> 21745500

Inhibitory effects of tricin derivative from Sasa albo-marginata on replication of human cytomegalovirus.

Kazuhiko Akuzawa1, Rie Yamada, Zhuan Li, Ying Li, Hidetaka Sadanari, Keiko Matsubara, Kunitomo Watanabe, Mamoru Koketsu, Yuuzo Tuchida, Tsugiya Murayama.   

Abstract

The anti-human cytomegalovirus (HCMV) activity of tricin (4',5,7-trihydroxy-3',5'-dimethoxyflavone), a derivative from Sasa albo-marginata, was studied in the human embryonic fibroblast cell line MRC-5. In a plaque assay, tricin and ganciclovir (GCV) showed concentration-dependent inhibitory properties from 0.05 to 3.6 μM and 0.01 to 1.0 μM, respectively. Tricin had no virucidal effects on cell-free HCMV. Treatment with tricin 1h before, or 1h or 3h after viral infection significantly suppressed HCMV replication. Moreover, tricin inhibited the expression of immediate early (IE) 2 mRNA and DNA polymerase (UL54) mRNA in HCMV-infected cells. Western blot analysis also demonstrated that tricin decreased the expression of IE antigen (especially IE2) and cyclooxygenase 2 (COX-2) expression in HCMV-infected cells. In the presence of tricin, prostaglandin E2 (PGE2) accumulation by HCMV infection was completely inhibited. These results suggest that tricin is a novel compound with potential COX inhibitor-dependent anti-HCMV activity. Crown
Copyright © 2011. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745500     DOI: 10.1016/j.antiviral.2011.06.014

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  2 in total

Review 1.  Natural Products and Their Derivatives against Human Herpesvirus Infection.

Authors:  Chattarin Ruchawapol; Man Yuan; Si-Min Wang; Wen-Wei Fu; Hong-Xi Xu
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

2.  The anti-human cytomegalovirus drug tricin inhibits cyclin-dependent kinase 9.

Authors:  Hidetaka Sadanari; Kazuhiro J Fujimoto; Yuto Sugihara; Tomoki Ishida; Masaya Takemoto; Tohru Daikoku; Tsugiya Murayama
Journal:  FEBS Open Bio       Date:  2018-02-20       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.